23 episódios

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast PeerView Press

    • Ciência

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    Robin Lachmann, MD, PhD / Melissa Wasserstein, MD - Assessing the Potential Role of Emerging Therapies in the Early Diagnosis and Optimal Management of Chronic Visceral Acid Sphingomyelinase Deficiency

    Robin Lachmann, MD, PhD / Melissa Wasserstein, MD - Assessing the Potential Role of Emerging Therapies in the Early Diagnosis and Optimal Management of Chronic Visceral Acid Sphingomyelinase Deficiency

    Go online to PeerView.com/NPH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic visceral acid sphingomyelinase deficiency (ASMD), also referred to as Niemann-Pick disease type B, is a rare and progressive autosomal recessive lysosomal storage disorder that causes progressive accumulation of sphingomyelin and other lipids in tissues throughout the body and is associated with significant morbidity and reduced life expectancy. The diagnosis of chronic visceral ASMD is often delayed by months or years, because its complex signs and symptoms overlap with other diseases. In this activity, leading experts review current consensus recommendations for the diagnosis of ASMD in pediatric and adult patients. The faculty also review the latest safety, efficacy, and tolerability data on emerging therapies and explore patient cases to offer practical strategies on how to optimally manage patients with chronic visceral ASMD. Upon completion of this activity, participants should be better able to: Diagnose individuals with ASMD through the application of recent consensus recommendations, Cite available efficacy, safety, and tolerability data on emerging therapeutic modalities for the treatment of patients with ASMD, Examine the potential impact that ongoing clinical trials of emerging therapeutic approaches may have on the future treatment of patients with ASMD.

    • 1h 2 min
    Pablo F. Mora, MD, FACE, CDE - Go Get the Glucagon! Current and Emerging Options for Treating Severe Hypoglycemia

    Pablo F. Mora, MD, FACE, CDE - Go Get the Glucagon! Current and Emerging Options for Treating Severe Hypoglycemia

    Go online to PeerView.com/CBF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist and certified diabetes educator discusses current and emerging treatment options for severe hypoglycemia. Upon completion of this activity, participants should be better able to: Recognize the role of glucagon for the treatment of severe hypoglycemia in patients with diabetes, Teach individuals outside of the hospital setting how and when to use glucagon to treat severe hypoglycemia, Evaluate the efficacy, safety, and ease of use of current and emerging glucagon rescue treatments for severe hypoglycemia

    • 33 min
    Rohit Loomba, MD, MHSc - Navigating Diagnosis and Examining the Data: The Clinical Potential of Novel Therapeutic Strategies to Improve Nonalcoholic Steatohepatitis Outcomes

    Rohit Loomba, MD, MHSc - Navigating Diagnosis and Examining the Data: The Clinical Potential of Novel Therapeutic Strategies to Improve Nonalcoholic Steatohepatitis Outcomes

    Go online to PeerView.com/GZX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in hepatology discusses current and emerging strategies to diagnose, treat, and manage patients with nonalcoholic steatohepatitis (NASH). Upon completion of this activity, participants should be better able to: Correctly diagnose and stage nonalcoholic fatty liver disease (NAFLD), distinguishing the subset of patients with NASH for disease monitoring and prognostication, Apply best practices in the management of patients with NASH based on evolving data on lifestyle modification and medical treatment, Evaluate data on emerging therapies for NASH, including evidence of reversal of fibrosis, risks and benefits, and their potential utility in the treatment of patients with NASH

    • 27 min
    Jerry Vockley, MD, PhD - Novel Strategies and Emerging Evidence to Address Unmet Needs in Treating Patients With Long-Chain Fatty Acid Oxidation Disorders

    Jerry Vockley, MD, PhD - Novel Strategies and Emerging Evidence to Address Unmet Needs in Treating Patients With Long-Chain Fatty Acid Oxidation Disorders

    Go online to PeerView.com/QXV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in medical genetics and inborn metabolism errors discusses novel strategies and emerging evidence for the identification and management of patients with long-chain fatty acid oxidation disorders. Upon completion of this activity, participants should be better able to: Recognize the signs and symptoms associated with the clinical presentation of long-chain fatty acid oxidation disorders (LC-FAOD), Review current recommendations for screening, diagnosis, and treatment of patients with LC-FAODs, Summarize the mechanism of action and emerging evidence for novel agents designed to address unmet needs among patients with LC-FAODs

    • 30 min
    Jay B. Wish, MD - Exploring Emerging Strategies in the Management of Anemia in Chronic Kidney Disease

    Jay B. Wish, MD - Exploring Emerging Strategies in the Management of Anemia in Chronic Kidney Disease

    Go online to PeerView.com/ETT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Anemia is a common complication of chronic kidney disease (CKD), which represents a major worldwide burden on public health, particularly in aging populations. Anemia affects the majority of patients with advanced CKD and is associated with increased cardiovascular risk, hospitalization, and mortality. Anemia in CKD is predominantly because of a relative deficiency in erythropoietin (EPO) production by the kidney, although concomitant functional and/or absolute iron deficiency and systemic and local inflammation also frequently contribute to its induction and maintenance. The current standard of care for anemia secondary to CKD is the use of injectable erythropoiesis-stimulating agents (ESAs), alone or in combination with intravenous or oral iron supplementation. While ESAs have been shown to be effective in treating anemia for many patients with CKD, they have some well-recognized limitations. Thus, alternative treatments that limit EPO exposure would be useful additions to the therapeutic armamentarium for anemia in CKD. Stabilization of hypoxia-inducible factor (HIF) via prolyl-hydroxylase (PH) domain inhibition represents a potentially promising new therapeutic approach to treat anemia secondary to CKD. Activation of HIF orchestrates a coordinated response to promote erythropoiesis through the stimulation of endogenous EPO production, increased uptake of iron, and mobilization of iron stores. Indeed, several HIF-PH inhibitors are currently in development for the treatment of anemia in CKD, and available clinical trial data suggest that HIF-PH inhibitors offer a number of advantages over ESAs. In this activity, based on a live symposium, experts offer insight into best practices regarding the treatment of CKD-associated anemia and the important emerging evidence for HIF-PH inhibitors in settings where conventional ESA therapy is often of limited efficacy. Foundational guidance is combined with a discussion of real cases. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia as a result of CKD, Summarize current clinical trial data regarding the efficacy and safety of HIF-PH inhibitors for the treatment of anemia because of CKD in both nondialysis-dependent and dialysis-dependent patients, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

    • 1h 12 min
    Mikhail Kosiborod, MD, FACC, FAHA - Reducing Cardiovascular Risks in Patients With Type 2 Diabetes: Identifying Your Role on the Diabetes Management Team

    Mikhail Kosiborod, MD, FACC, FAHA - Reducing Cardiovascular Risks in Patients With Type 2 Diabetes: Identifying Your Role on the Diabetes Management Team

    Go online to PeerView.com/YNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView onDemand activity, based on an educational session from the 2019 Scientific Sessions of the American Heart Association in Philadelphia, Pennsylvania, features a panel of cardiology, endocrinology, and primary care experts, who provide their clinical perspectives on assessing patients with type 2 diabetes mellitus (T2DM) who are at high risk for cardiovascular (CV) disease and other risk factors. These experts discuss recent and emerging data for antihyperglycemic agents (ie, GLP-1 receptor agonists and SGLT2 inhibitors) and how to incorporate this practice-changing information into individualized treatment plans for these high-risk patients. Upon completion of this activity, participants should be better able to: Screen patients with or at high risk of CV disease for T2DM, Assess individual patients with T2DM for risk factors that frequently complicate diabetes management (ie, history of atherosclerotic CV disease, heart failure, chronic kidney disease, hypoglycemia, obesity), Design individualized treatment regimens that consider and incorporate recent and emerging data for antihyperglycemic agents that have been shown to reduce CV risk in patients with T2DM, Collaborate with multidisciplinary colleagues to successfully reduce CV risk in individual patients with T2DM

    • 1h 18 min

Top podcasts em Ciência

Ouvintes também assinaram

Mais de PeerView Press